Calreticulin mutant myeloproliferative neoplasms induce MHC-I skewing, which can be overcome by an optimized peptide cancer vaccine.

Published in:

Science Translational Medicine, 2022, v. 14, n. 649, p. 1, doi. 10.1126/scitranslmed.aba4380

By:

• Gigoux, Mathieu;
• Holmström, Morten O.;
• Zappasodi, Roberta;
• Park, Joseph J.;
• Pourpe, Stephane;
• Bozkus, Cansu Cimen;
• Mangarin, Levi M. B.;
• Redmond, David;
• Verma, Svena;
• Schad, Sara;
• George, Mariam M.;
• Venkatesh, Divya;
• Ghosh, Arnab;
• Hoyos, David;
• Molvi, Zaki;
• Kamaz, Baransel;
• Marneth, Anna E.;
• Duke, William;
• Leventhal, Matthew J.;
• Jan, Max

Publication type:

Article